Periciazine and Breastfeeding

Summary of use during lactation

Propericiazine and its active metabolite periciazine are not approved for marketing in the United States by the U.S. Food and Drug Administration, but are available in other countries. Minimal information from one patient indicates that the amount of periciazine is low in milk after administration of propericiazine. If propericiazine or periciazine is required by the mother, it is not a reason to discontinue breastfeeding, but until more data become available, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.

Drug levels in milk and infant serum

Propericiazine is metabolized to the active drug, periciazine in the body. Maternal Levels. A woman with dissociative disorder and persistent dysthymic depression was treated during pregnancy with brotizolam 0.25 mg daily, propericiazine 10 mg daily, and zolpidem 5 mg daily. Zolpidem was discontinued at week 28 and sulpiride 100 mg daily was begun at week 33. Milk samples taken at 7.5 and 11.5 hours after the previous dose on day 9 postpartum contained 0.3 and 0.1 mcg/L of periciazine, respectively.[1] Infant Levels. Relevant published information was not found as of the revision date.

Effects in breastfed infants

Relevant published information was not found as of the revision date.

Effects on lactation and breastmilk

Relevant published information was not found as of the revision date.

Alternative drugs to consider

Haloperidol, Olanzapine, Quetiapine, Risperidone

References

1. SaitoJ TachibanaY WadaYS Transfer of brotizolam, periciazine, and sulpiride in cord blood and breast milk, and alprazolam in breast milk: A case report. J Pharm Health Care Sci 2022 8 10 35361275 PubMed